Abstract 927: Real-world (RW) biomarker characteristics and clinical outcomes in pre-treated non-MSI-H/dMMR metastatic colorectal cancer (mCRC) patients

Abstract Introduction: Given sparse RW evidence, we assessed biomarker characteristics 2 visits, 70. 9% received MSI/MMR testing. In 292 eligible chart review patients, 69. 5% received SACT in pre-treated setting (regorafenib 14. 8%, trifluridine/tipiracil (TAS-102) 12. 3%, other 72. 9%), 28. 8% received BSC all highlighting an unmet need. Cohorts Median (95% CI) OS (months) Median (95% CI) rwPFS1 (months) Overall 7. 4 (5. 8, 8. 8) 3. 5 (3. 2, 4. 3) Regorafenib 5. 6 (3. 1, 9. 7) 2. 4 (1. 8, 3. 0) TAS-102 5. 9 (3. 4, 8. 6) 3. 0 (2. 1, 3. 4) Other SACT2 12. 8 (9. 8, 17. 2) 4. 9 (3. 7, 5. 8) BSC 2. 4 (1. 8, 3. 2) - RAS mutation Wild-type 8. 6 (6. 6, 11. 5) 4. 0 (3. 3, 4. 9) Mutant 5. 4 (3. 4, 9. 5) 3. 2 (2. 1, 4. 6) Metastatic sites Liver only 8. 0 (5. 7, 11. 7) 3. 9 (3. 0, 4. 9) Lung only 17. 0 (7. 8, 35. 6) 7. 9 (3. 3, 10. 5) Liver Part 1 (Regular Abstracts) ; 2024 Apr 5-10; San Diego, CA. Philadelphia (PA): AACR; Cancer Res 2024;84 (6Suppl): Abstract nr 927.